Moncef Slaoui

Q: What Schools Are Affiliated With Moncef Slaoui

Moncef Slaoui is affiliated with the following schools: Université libre de Bruxelles, International Institute for Management Development, University of Mons

Moncef Slaoui's AcademicInfluence.com Rankings

Moncef Slaoui

Biology

#1964

World Rank

#3165

Historical Rank

Immunology

#265

World Rank

#276

Historical Rank

Microbiology

#1119

World Rank

#1260

Historical Rank

biology Degrees

Moncef Slaoui

Philosophy

#11962

World Rank

#16546

Historical Rank

Logic

#9377

World Rank

#11880

Historical Rank

philosophy Degrees

Download Badge

Biology
Philosophy

Why Is Moncef Slaoui Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Moncef Mohamed Slaoui is a Moroccan-born Belgian-American researcher who served as the head of Operation Warp Speed under President Donald Trump from 2020 to 2021. Slaoui is the former head of the vaccines department at GlaxoSmithKline . He worked at the company for thirty years, retiring in 2017. On May 15, 2020, President Donald Trump announced that Slaoui would manage the U.S. government's development of a vaccine used to treat coronavirus disease in OPWASP; Slaoui resigned on January 12, 2021 after successfully having helped introduce a number of vaccines to the US and global markets. In March 2021, he was fired from the board of GSK subsidiary Galvani Bioelectronics over what GSK called “substantiated” sexual harassment allegations stemming from his time at the parent company.

(See a Problem?)

Moncef Slaoui's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. (1997) (883)
Glycoprotein-D-adjuvant vaccine to prevent genital herpes. (2002) (559)
Drug discovery: A jump-start for electroceuticals (2013) (447)
Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. (1995) (297)
Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. (1998) (259)
Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. (1999) (168)
Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. (1998) (158)
Nucleic acid sequence of an internal image-bearing monoclonal anti-idiotype and its comparison to the sequence of the external antigen. (1986) (153)
Developing Safe and Effective Covid Vaccines - Operation Warp Speed's Strategy and Approach. (2020) (113)
Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. (2003) (111)
Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine (1996) (101)
Evidence for induction of polysaccharide specific B-cell-memory in the 1st year of life: plain Haemophilus influenzae type b - PRP (Hib) boosters children primed with a tetanus-conjugate Hib-DTPa-HBV combined vaccine (1996) (97)
Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs. (1995) (92)
Pulmonary lesions in primary respiratory syncytial virus infection, reinfection, and vaccine-enhanced disease in the cotton rat (Sigmodon hispidus). (1999) (87)
Seroprevalence of herpes simplex virus types 1 and 2 and cytomegalovirus in adolescents. (1997) (83)
Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine. (1997) (83)
Vaccination with recombinant vaccinia viruses expressing ICP27 induces protective immunity against herpes simplex virus through CD4+ Th1+ T cells (1995) (82)
The potential epidemiological impact of a genital herpes vaccine for women (2004) (78)
Idiotypes, recurrent idiotypes and internal images. (1982) (73)
A hepatitis B vaccine formulated with a novel adjuvant system. (2000) (65)
Identification of different target glycoproteins for bovine herpes virus type 1-specific cytotoxic T lymphocytes depending on the method of in vitro stimulation. (1993) (54)
Efficacy of a recombinant glycoprotein D subunit vaccine on the development of primary and recurrent ocular infection with herpes simplex virus type 1 in mice. (1997) (51)
Mutations located on both F1 and F2 subunits of the Newcastle disease virus fusion protein confer resistance to neutralization with monoclonal antibodies (1989) (51)
Monophosphoryl lipid A adjuvant reverses a principal histologic parameter of formalin-inactivated respiratory syncytial virus vaccine-induced disease. (2001) (51)
Enumeration of lymphokine‐secreting cells as a quantitative measure for cellular immune responses in rhesus macaques (1995) (46)
Complete amino acid sequence of heavy chain variable regions derived from two monoclonal anti-p-azophenylarsonate antibodies of BALB/c mice expressing the major cross-reactive idiotype of the A/J strain (1984) (44)
Idiotypic analysis of polyclonal and monoclonal anti-p-azophenylarsonate antibodies of BALB/c mice expressing the major cross-reactive idiotype of the A/J strain. (1985) (40)
Cell-mediated immunity after pertussis vaccination and after natural infection. (1997) (28)
Idiotypy and internal images (1984) (27)
Idiotypic analysis of potential and available repertoires in the arsonate system (1984) (26)
From Clonal Selection to Immune Networks: Induction of Silent Idiotypes a (1983) (19)
Structural characterization of antiidiotypic antibodies. Evidence that Ab2s are derived from the germline differently than Ab1s (1989) (17)
Cellular immune response of a varicella vaccine following simultaneous DTaP and VZV vaccination. (1999) (16)
Hepatitis B virus-specific cytotoxic T lymphocyte responses in patients with acute and chronic hepatitis B virus infection. (1994) (16)
Bridging the Gap at Warp Speed - Delivering Options for Preventing and Treating Covid-19. (2020) (15)
Genetic and biological characterization of a T suppressor cell induced by anti-idiotypic antibody. (1985) (13)
Idiotypic Games within the Immune Network (1986) (13)
Accelerating development, registration and access to medicines for rare diseases in the European Union through adaptive approaches: features and perspectives (2014) (10)
European Commission COST/STD Initiative. Report of the expert panel VII. Vaccine delivery systems. (1996) (7)
CD4-Ia interactions can occur in the absence of T-cell receptor/antigen-Ia recognition. (1989) (7)
Efficacy of the herpes simplex virus types 1 and 2 mutant viruses to confer protection against zosteriform spread in mice. (1993) (5)
Anti-idiotypic treatment of BALB/c mice induces CRIa-bearing suppressor cells with altered Igh-restricted function. (1986) (5)
Study of idiotopic suppression induced by anti-cross-reactive idiotype monoclonal antibody in the anti-p-azophenylarsonate antibody response. (1986) (5)
Loss of a major idiotype (CRIA) after repopulation of irradiated mice. (1990) (5)
Studies of the Arsonate System Using Monoclonal Antibodies a (1983) (4)
The rise and fall of rosiglitazone: reply. (2010) (3)
Some aspects of idiotypic networks: self/non-self discrimination, selection of available repertoires and broken mirrors. (1988) (3)
Recent advances with new vaccine adjuvants: from preclinical to clinical development (1998) (2)
Idiotypic manipulations in the arsonate system. (1984) (2)
Cellular and molecular interactions in suppressor T cell-mediated immunoregulation: perspectives in autoimmunity. (1985) (2)
Moncef Slaoui (2015) (2)
In vivo induction of A/J anti-ARS responses with different ranges of affinities: correlation between affinity and CRIA idiotype dominance. (1989) (2)
Effect of Zinc Doping on the Electrical and Dielectric Properties of CCTO Compound Synthesized by Solid-State Method (2021) (1)
Evaluation of protection conferred by several acellular pertussis vaccines in an intranasal model of B. pertussis infection. (1999) (1)
Development and efficacy assessment of combination vaccines, with emphasis on acellular pertussis. (1998) (1)
A tumor-associated, antigen from the MAGE family, used to prepare fusion proteins with T-helper epitopes and compositions for vaccination (1999) (0)
Process for the vaccine composition valmistamikseksi (1994) (0)
Vaccine composition adjuvants. (1993) (0)
A process for the purification or the preparation of the MAGE protein (1999) (0)
Author Correction: Supporting US public health experts (2020) (0)
Supporting US public health experts (2020) (0)
Idiotypic studies of monoclonal anti-tobacco mosaic virus antibodies from one mouse. (1983) (0)
3-0 Deazylierte monophosphoryl lipid A containing vaccine compositions (1994) (0)
Methods and compositions for inducing protective immunity against disease and / or infection filoviruses (2016) (0)
The vaccine composition containing the excipient (1994) (0)
A method for purifying or producing a MAGE protein (1999) (0)
A Method to Detect Hepatitis B Virus-specific Cytotoxic T Lymphocytes in Patients with Acute and Chronic HBV Infection (1994) (0)
, P acellular pertussis vaccine . infants after vaccination with a tricomponent Pertussis-specific cell-mediated immunity in (1996) (0)
Influenza vaccine compositions for intradermal administration (2002) (0)
Bordetella pertussis except membrane protein fragments containing vaccine composition (1997) (0)
Adjuvants containing vaccine composition (1993) (0)
Herpes simplex vaccine, the hsv-glycoprotein-gd and 3-deacyl monophosphoryl lipid A contains. (1992) (0)
Derivatives of tumor associated antigens of the MAGE family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and vaccine compositions. (1999) (0)
Synthesis and Physico-chemical Characterization of Solid Solution (1-x)CCTO−xPbTiO3 (2021) (0)
A method for preparing a Herpes simplex vaccine comprising HSV glycoprotein GD and 3-deacylated monophosphoryl lipid A (1993) (0)
From idiotypes to idiotypic network (1986) (0)
Influenza virus vaccine composition for nasal application (2000) (0)
Mutations Located on BothFlandF2Subunits oftheNewcastle Disease VirusFusion Protein Confer Resistance toNeutralization withMonoclonal Antibodies (1989) (0)
Purification procedure or producing an mage protein. (1999) (0)
Tumor-associated antigen derivatives of the mage-family nucleic acid sequences that code for the production of fusion proteins and compositions for vaccination (1999) (0)

This paper list is powered by the following services:

Other Resources About Moncef Slaoui

en.wikipedia.org

What Schools Are Affiliated With Moncef Slaoui?

Moncef Slaoui is affiliated with the following schools:

Moncef Slaoui's Academic­Influence.com Rankings

Why Is Moncef Slaoui Influential?

Moncef Slaoui's Published Works

Published Works

Other Resources About Moncef Slaoui

What Schools Are Affiliated With Moncef Slaoui?

Image Attributions

Moncef Slaoui's AcademicInfluence.com Rankings